A centenarian club

When Russell Snell and his colleagues at the University of Auckland, New Zealand, were recently designing a study to test a candidate Alzheimer's gene, they ran up against a roadblock: How to put together a control group? "It's a problem," says Snell. "How do you identify a person who is not going to develop Alzheimer's?" Need 100-year-old research subjects? Try Medicine. The obvious answer was to find a group of healthy people who had passed the usu

Written byStephen Pincock
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

When Russell Snell and his colleagues at the University of Auckland, New Zealand, were recently designing a study to test a candidate Alzheimer's gene, they ran up against a roadblock: How to put together a control group? "It's a problem," says Snell. "How do you identify a person who is not going to develop Alzheimer's?"

The obvious answer was to find a group of healthy people who had passed the usual age of onset of the disease. "If you reach 95 or 100, or more, and you don't have Alzheimer's then you probably won't be getting it," he says. But gathering a sizeable cohort of centenarians and near-centenarians is no easy matter, certainly not in New Zealand, with a population of just 4.16 million. So Snell took to the literature, searching for other groups who had a cohort he might borrow.

He found the perfect sample in May 2005, when ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies